Bharat Biotech’s Covid-19 vaccine ‘Covaxin’ enters phase-3 trials
PTI, Nov 16, 2020, 4:10 PM IST
New Delhi: Covid-19 vaccine, Covaxin, being developed by Bharat Biotech is now undergoing phase-3 trials, Krishna Ella, Chairman and Managing Director, Bharat Biotech said on Monday.
Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for Covid-19 which would be in the form of nasal drops and can be ready by next year.
“We partnered with ICMR for Covid-19 vaccine as we speak it entered the phase 3 trials,” he said.
Bharat Biotech is the only vaccine company in the world which has BSL3 production facility (Biosafety level 3), he said.
Last month the vaccine maker said it had successfully completed interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participants.
Covaxinis being developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
The city-based vaccine maker had on October 2 sought the Drug Controller General of India’s (DCGI) permission to conduct phase 3 randomised double-blind placebo-controlled multicentre trial of its Covid-19 vaccine, sources said.
“We are working on another vaccine through nasal drops my feeling is by next year it will reach the population,” Ella said.
Bharat Biotech in September said it entered into a licensing agreement with Washington University School of Medicine in St. Louis for a novel “chimp-adenovirus” (Chimpanzee adenovirus), single-dose intranasal vaccine for Covid-19.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Congress to discuss candidates for Amethi, Raebareli seats on Saturday
Cache of arms including foreign-made revolvers seized by CBI in Sandeshkhali raids
24 Indian Fishermen Released from Sri Lankan Detention, Repatriated to India
SC verdict on EVM tight slap to Congress-led opposition: PM Modi in Bihar rallies
Board exams twice a year from 2025: MoE asks CBSE to work out logistics, no plan for semesters
MUST WATCH
Latest Additions
Patanjali Foods to evaluate proposal to buy Patanjali Ayurved’s non-food business
Congress to discuss candidates for Amethi, Raebareli seats on Saturday
BJP’s CT Ravi Booked for Promoting Hatred and Enmity Through Social Media Post
Elections held in 14 LS segments in Karnataka, voter turnout nearly 64 per cent till 5 pm
‘PM is scared, may even shed tears on stage’: Rahul Gandhi’s fresh salvo at Modi